SMT201600034B - Metodi di trattamento del cancro mediante l’uso di 3-(5-ammino-2-metil-4-oxo-4h-chinazolin-3-il)-piperidin-2,6-dione - Google Patents

Metodi di trattamento del cancro mediante l’uso di 3-(5-ammino-2-metil-4-oxo-4h-chinazolin-3-il)-piperidin-2,6-dione

Info

Publication number
SMT201600034B
SMT201600034B SM201600034T SM201600034T SMT201600034B SM T201600034 B SMT201600034 B SM T201600034B SM 201600034 T SM201600034 T SM 201600034T SM 201600034 T SM201600034 T SM 201600034T SM T201600034 B SMT201600034 B SM T201600034B
Authority
SM
San Marino
Prior art keywords
chinazolin
dion
piperidin
oxo
cancer
Prior art date
Application number
SM201600034T
Other languages
English (en)
Italian (it)
Inventor
George W Muller
Peter H Schafer
Hon-Wah Man
Ling-Hua Zhang
Anita Gandhi
Rajesh Chopra
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SMT201600034B publication Critical patent/SMT201600034B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Medical Informatics (AREA)
  • Electromagnetism (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
SM201600034T 2011-03-11 2016-02-09 Metodi di trattamento del cancro mediante l’uso di 3-(5-ammino-2-metil-4-oxo-4h-chinazolin-3-il)-piperidin-2,6-dione SMT201600034B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451995P 2011-03-11 2011-03-11
US201161480272P 2011-04-28 2011-04-28
PCT/US2012/028498 WO2012125459A1 (fr) 2011-03-11 2012-03-09 Méthodes de traitement du cancer au moyen de 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Publications (1)

Publication Number Publication Date
SMT201600034B true SMT201600034B (it) 2016-04-29

Family

ID=45876915

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600034T SMT201600034B (it) 2011-03-11 2016-02-09 Metodi di trattamento del cancro mediante l’uso di 3-(5-ammino-2-metil-4-oxo-4h-chinazolin-3-il)-piperidin-2,6-dione

Country Status (29)

Country Link
US (6) US8906932B2 (fr)
EP (3) EP2683384B1 (fr)
JP (5) JP6118273B2 (fr)
KR (2) KR20140025374A (fr)
CN (3) CN103561744A (fr)
AR (1) AR085651A1 (fr)
AU (4) AU2012229300B2 (fr)
BR (2) BR112013023280A2 (fr)
CA (2) CA2829592A1 (fr)
CY (1) CY1117430T1 (fr)
DK (1) DK2683384T3 (fr)
EA (2) EA201691939A1 (fr)
ES (2) ES2659205T3 (fr)
HK (1) HK1191858A1 (fr)
HR (1) HRP20160056T1 (fr)
HU (1) HUE027481T2 (fr)
IL (2) IL227990B (fr)
MX (2) MX2013010217A (fr)
NI (2) NI201300082A (fr)
PL (1) PL2683384T3 (fr)
PT (1) PT2683384E (fr)
RS (1) RS54553B1 (fr)
RU (3) RU2013145524A (fr)
SG (2) SG193320A1 (fr)
SI (1) SI2683384T1 (fr)
SM (1) SMT201600034B (fr)
TW (2) TWI542349B (fr)
WO (2) WO2012125475A1 (fr)
ZA (2) ZA201306148B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE555104T1 (de) 2006-09-26 2012-05-15 Celgene Corp 5-substituierte chinazolinon-derivate als antitumorverbindungen
WO2010137547A1 (fr) 2009-05-25 2010-12-02 国立大学法人東京工業大学 Composition pharmaceutique contenant un facteur nucléaire impliqué dans la prolifération et la différentiation de cellules neuronales centrales
WO2012125438A1 (fr) 2011-03-11 2012-09-20 Celgene Corporation Formes solides de 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, leurs compositions pharmaceutiques et leurs utilisations
EP2699091B1 (fr) 2011-03-28 2017-06-21 DeuteRx, LLC Composés de 2',6'-dioxo-3'-deutéro-pipéridin-3-yl-isoindoline
CA2834535A1 (fr) * 2011-04-29 2012-11-01 Celgene Corporation Procedes de traitement du cancer et de maladies inflammatoires au moyen de cereblon en tant que predicteur
EP2867671B1 (fr) 2012-06-29 2018-10-24 Celgene Corporation Procédés pour déterminer l'efficacité d'un médicament en utilisant des protéines associées au céréblon
IL288506B2 (en) * 2012-08-09 2023-09-01 Celgene Corp Methods for treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoisoindolin-2-yl)piperidine-2,6-dione
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
EP2892887B1 (fr) 2012-09-04 2020-07-15 Celgene Corporation Isotopologues de 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione et leurs methodes de preparation
KR20150054962A (ko) * 2012-09-10 2015-05-20 셀진 코포레이션 국소 진행성 유방암의 치료방법
WO2014110558A1 (fr) 2013-01-14 2014-07-17 Deuterx, Llc Dérivés de 3-(5-substituté-4-oxoquinazolin-3(4h)-yl)-3-deutéro-pipéridine-2,6-dione
CA2941560A1 (fr) 2013-03-14 2014-09-25 Deuterx, Llc Derives de 3-(oxoquinazolin-3(4h)-yl-4 substitue)-3-deutero-piperidine-2,6-dione et des compositions les comprenant et des procedes les utilisant
KR102242505B1 (ko) * 2013-04-17 2021-04-20 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법
AU2014253978B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer
RS56565B1 (sr) * 2013-05-01 2018-02-28 Celgene Corp Sinteza 3-(5-amino-2-metil-4-oksohinazolin-3(4h)-il)piperidin-2,6-diona
JP2016521280A (ja) * 2013-05-03 2016-07-21 セルジーン コーポレイション 併用療法を用いて癌を治療する方法
US20160282354A1 (en) 2013-11-08 2016-09-29 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
AU2014360328B2 (en) * 2013-12-06 2021-04-01 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
AR099385A1 (es) * 2014-01-15 2016-07-20 Celgene Corp Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
EP3827836A1 (fr) 2014-06-27 2021-06-02 Celgene Corporation Compositions et procédés pour induire des modifications conformationnelles dans céréblon et d'autres ubiquitine ligases e3
KR20170029565A (ko) * 2014-07-11 2017-03-15 셀진 코포레이션 암 치료를 위한 병용요법
FI3182996T3 (fi) 2014-08-22 2023-03-28 Celgene Corp Menetelmiä multippelin myelooman hoitamiseksi immuunivastetta muuntavilla yhdisteillä yhdistelmässä vasta-aineiden kanssa
MX2017005163A (es) * 2014-11-17 2018-01-18 Arno Therapeutics Inc Composiciones de liberación prolongada de onapristona y métodos.
TW201642857A (zh) * 2015-04-06 2016-12-16 西建公司 以組合療法治療肝細胞癌
BR112017028530A2 (pt) * 2015-07-02 2018-08-28 Celgene Corp terapia combinada para tratamento de cânceres hematológicos e tumores sólidos
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US10064863B2 (en) * 2015-08-27 2018-09-04 Celgene Corporation Formulations of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
EP3347717A4 (fr) * 2015-09-11 2019-06-05 The Brigham and Women's Hospital, Inc. Procédés de caractérisation d'une résistance à des modulateurs de céréblon
BR112018005999A2 (pt) 2015-09-25 2019-01-08 Context Biopharma Inc métodos para a produção de intermediários de onapristona
JP2018535992A (ja) 2015-12-02 2018-12-06 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを使用するサイクリング療法
CN108883067B (zh) 2015-12-15 2021-03-09 康特斯生物制药公司 非晶奥那司酮组合物及其制备方法
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
PL3404024T3 (pl) * 2016-01-14 2021-04-19 Kangpu Biopharmaceuticals, Ltd. Pochodna chinazolinonu, sposób jej przygotowania, kompozycja farmaceutyczna i zastosowania
EP3429996A4 (fr) * 2016-03-16 2020-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Petites molécules dirigées contre le céréblon pour améliorer la fonction des lymphocytes t effecteurs
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
WO2018165142A1 (fr) * 2017-03-07 2018-09-13 Celgene Corporation Formes solides de 3-(5-amino-2-méthyl-4-oxo-4h-quinazolin-3-yl)-pipéridine-2,6-dione, leurs compositions pharmaceutiques et leurs utilisations
BR112019027402A2 (pt) * 2017-06-22 2020-07-07 Celgene Corporation tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b
WO2019077968A1 (fr) 2017-10-18 2019-04-25 Canon Kabushiki Kaisha Contenant d'emballage et paquet
AU2019243186A1 (en) * 2018-03-30 2020-10-15 Biotheryx, Inc. Thienopyrimidinone compounds
KR20210032430A (ko) 2018-07-11 2021-03-24 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 세레블론-기반 메커니즘에 대한 이량체 면역-조절 화합물
JP7323603B2 (ja) * 2018-09-07 2023-08-08 メッドシャイン ディスカバリー インコーポレイテッド 三環式縮合フラン置換ピペリジンジオン系化合物
AU2019351811A1 (en) 2018-10-01 2021-05-06 Celgene Corporation Combination therapy for the treatment of cancer
WO2020197227A1 (fr) * 2019-03-22 2020-10-01 울산대학교 산학협력단 Biomarqueur céréblon pour le diagnostic d'un carcinome hépatocellulaire, et nouvel anticorps monoclonal spécifique de celui-ci
WO2021198188A1 (fr) * 2020-03-30 2021-10-07 Enyo Pharma Dérivés de quinazolinone et leurs utilisations pour le traitement d'un cancer
WO2024040036A2 (fr) * 2022-08-16 2024-02-22 iTeos Belgium SA Antagonistes du récepteur de l'adénosine et compositions associées destinées à être utilisées dans le traitement d'une maladie associée à l'expression d'au moins un marqueur cellulaire sécrétant un anticorps

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (fr) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Formulation a liberation-retard
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
ATE233088T1 (de) 1996-12-20 2003-03-15 Takeda Chemical Industries Ltd Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP2141243A3 (fr) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Supports de protéine pour mimer des anticorps et d'autres protéines de liaison
YU45103A (sh) * 2000-12-06 2006-08-17 Applied Research Systems Ars Holding N.V. Upotreba sarp/1 za lečenje i prevenciju skleroderme
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP2008520207A (ja) 2004-11-16 2008-06-19 アヴィディア リサーチ インスティテュート タンパク質骨格およびその使用
US20080051379A1 (en) 2004-12-01 2008-02-28 Trustees Of Boston University Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
ATE555104T1 (de) * 2006-09-26 2012-05-15 Celgene Corp 5-substituierte chinazolinon-derivate als antitumorverbindungen
GB0709092D0 (en) * 2007-05-11 2007-06-20 Borrebaeck Carl Diagnosis and method of disease
NZ584425A (en) * 2007-09-26 2012-03-30 Celgene Corp 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
MX2010006092A (es) * 2007-12-07 2010-07-05 Celgene Corp Biomarcadores para monitorear el tratamiento mediante compuestos de quinazolinona.
WO2010137547A1 (fr) 2009-05-25 2010-12-02 国立大学法人東京工業大学 Composition pharmaceutique contenant un facteur nucléaire impliqué dans la prolifération et la différentiation de cellules neuronales centrales
CA2834535A1 (fr) * 2011-04-29 2012-11-01 Celgene Corporation Procedes de traitement du cancer et de maladies inflammatoires au moyen de cereblon en tant que predicteur

Also Published As

Publication number Publication date
US20140148473A1 (en) 2014-05-29
WO2012125459A1 (fr) 2012-09-20
NZ614347A (en) 2015-09-25
BR112013023280A2 (pt) 2017-09-19
IL228230A (en) 2017-03-30
EP2683383B1 (fr) 2017-11-29
US8906932B2 (en) 2014-12-09
CY1117430T1 (el) 2017-04-26
US20120230983A1 (en) 2012-09-13
MX2013010153A (es) 2013-09-26
RU2013145524A (ru) 2015-04-20
AR085651A1 (es) 2013-10-16
ZA201306148B (en) 2014-10-29
CN103561744A (zh) 2014-02-05
EP2683384A1 (fr) 2014-01-15
AU2017210633A1 (en) 2017-08-24
ES2659205T3 (es) 2018-03-14
KR20140019364A (ko) 2014-02-14
TWI542349B (zh) 2016-07-21
EA201691939A1 (ru) 2017-05-31
JP6348192B2 (ja) 2018-06-27
NI201300081A (es) 2014-02-25
US20170165266A1 (en) 2017-06-15
JP2014510078A (ja) 2014-04-24
PT2683384E (pt) 2016-03-11
JP2017081959A (ja) 2017-05-18
CA2829592A1 (fr) 2012-09-20
JP2018168159A (ja) 2018-11-01
MX2013010217A (es) 2013-10-25
EA201391319A1 (ru) 2014-03-31
US20160136167A1 (en) 2016-05-19
IL227990B (en) 2018-02-28
CN103561743A (zh) 2014-02-05
PL2683384T3 (pl) 2016-06-30
US20150126538A1 (en) 2015-05-07
AU2012229316B2 (en) 2017-05-11
ZA201306305B (en) 2014-10-29
SI2683384T1 (sl) 2016-05-31
BR112013023277A2 (pt) 2017-06-27
EP2683384B1 (fr) 2015-12-09
AU2012229300A1 (en) 2013-09-12
AU2012229300B2 (en) 2017-04-20
DK2683384T3 (da) 2016-02-08
JP2014508780A (ja) 2014-04-10
TW201700100A (zh) 2017-01-01
WO2012125475A1 (fr) 2012-09-20
EP3025715A1 (fr) 2016-06-01
AU2017204402A1 (en) 2017-07-20
RU2017120977A (ru) 2018-11-15
NZ614493A (en) 2016-01-29
SG193320A1 (en) 2013-10-30
RS54553B1 (en) 2016-06-30
HUE027481T2 (en) 2016-09-28
CN107375293A (zh) 2017-11-24
CA2829593A1 (fr) 2012-09-20
JP2017101052A (ja) 2017-06-08
HRP20160056T1 (hr) 2016-02-12
RU2013145556A (ru) 2015-04-20
US20180055844A1 (en) 2018-03-01
TW201242601A (en) 2012-11-01
IL227990A0 (en) 2013-09-30
EP2683383A1 (fr) 2014-01-15
JP6118273B2 (ja) 2017-04-19
AU2012229316A1 (en) 2013-09-19
NI201300082A (es) 2014-02-25
HK1191858A1 (zh) 2014-08-08
KR20140025374A (ko) 2014-03-04
SG192947A1 (en) 2013-09-30
ES2562332T3 (es) 2016-03-03

Similar Documents

Publication Publication Date Title
SMT201600034B (it) Metodi di trattamento del cancro mediante l’uso di 3-(5-ammino-2-metil-4-oxo-4h-chinazolin-3-il)-piperidin-2,6-dione
LTPA2019519I1 (lt) Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
IL288506B1 (en) Methods for treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoisoindolin-2-yl)piperidine-2,6-dione
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
BR112014007603A2 (pt) métodos de tratamento do câncer
BR112014009755A2 (pt) tratamento de câncer com inibidores de quinase tor
BR112014012880A2 (pt) tratamento imunogênico do câncer
DK2707030T3 (da) Cancerbehandlinger
DK2717941T3 (da) Behandling af cancer
DK2785349T4 (da) Kombinationsbehandling af cancer
DK2872497T4 (da) Chromanyl-derivater til behandling af mitokondriel sygdom
BR112013024211A2 (pt) tratamento de tumores sólidos
SMT201600235B (it) Predittori per il trattamento del cancro
DK2892535T3 (da) Fremgangsmåde til adjuverende cancerbehandling
SMT201600296B (it) Lapatinib per il trattamento del cancro
CO7071121A2 (es) Métodos para sintetizar derivados del precusor z de molibdopterina
SMT201500056B (it) Derivati 4-(metilamminofenossi)piridin-3-il benzammidici per il trattamento del cancro
SMT201600416B (it) Uso di sali di 3-carbossi-n-etil-n,n-dimetilpropan-1-amminio nel trattamento di malattie cardiovascolari
ES1076043Y (es) Jamonero desmontable de ajuste multiple.
CL2014001784A1 (es) Uso de compuestos derivados de imidazopiridina sustituidos para el tratamiento del cancer de vejiga.
SMT201600415B (it) Procedimento di preparazione di metaxalone
SMT201500039B (it) Uso del nifuratel per il trattamento di infenzionicausate dalle specie di clostridium
BR112013023162A2 (pt) métodos de terapia fotodinâmica focal
TH1401000996B (th) วิธีการสำหรับการผลิตซีเมนต์
EE01180U1 (et) Parkimisssteem